What is the appropriate management for a patient on tirzepatide (Mounjaro) who presents with left lower‑quadrant abdominal pain and diarrhea?

Management of Left Lower Quadrant Abdominal Pain and Diarrhea in a Patient on Tirzepatide

Immediately discontinue tirzepatide and assess for severe gastrointestinal complications, dehydration, and electrolyte disturbances, as these symptoms represent known and potentially serious adverse effects of this medication.

Immediate Assessment and Tirzepatide Discontinuation

Stop tirzepatide immediately when a patient presents with severe abdominal pain and diarrhea, as the FDA label explicitly warns that tirzepatide is associated with gastrointestinal adverse reactions, sometimes severe, and is not recommended in patients with severe gastroparesis 1. The most common adverse reactions occur in ≥5% of patients and include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain 1.

Critical Red Flags to Evaluate

Assess immediately for life-threatening complications:

• Acute pancreatitis: Persistent severe abdominal pain (sometimes radiating to the back) with or without vomiting requires immediate discontinuation of tirzepatide 1. This is a known serious adverse effect of GLP-1 receptor agonists and tirzepatide 2.

• Volume depletion and acute kidney injury: Monitor renal function as gastrointestinal adverse reactions leading to dehydration (nausea, vomiting, diarrhea) have caused acute kidney injury requiring hemodialysis in some cases 1. The majority of reported acute kidney injury events occurred in patients with gastrointestinal symptoms 2.

• Electrolyte disturbances: Check potassium, magnesium, and calcium levels urgently, as severe electrolyte imbalances from tirzepatide-induced vomiting and diarrhea can precipitate life-threatening ventricular arrhythmias 3. One case report documented ventricular fibrillation from profound electrolyte depletion (K⁺ 2.2, Mg²⁺ 1.1) caused by tirzepatide's gastrointestinal effects 3.

• Acute gallbladder disease: Left-sided pain can occasionally represent referred pain from gallbladder pathology. Tirzepatide increases the risk of gallbladder and biliary disease 2. If cholelithiasis is suspected, obtain gallbladder imaging 1.

Gastrointestinal Side Effect Profile of Tirzepatide

The gastrointestinal adverse events with tirzepatide are dose-dependent and extremely common:

• Diarrhea occurs in 16.24% of patients on tirzepatide versus 8.63% on comparators (RR 2.07) 4, with meta-analysis confirming significantly higher rates across all doses 5.

• Nausea affects 20.43% of tirzepatide patients versus 10.47% of controls (RR 2.90) 4, making it one of the most frequent adverse effects 6.

• Severe gastrointestinal adverse reactions occurred in 1.2-1.3% of patients on therapeutic doses in placebo-controlled trials 1.

• These symptoms are most pronounced during dose escalation and may improve over time with continued use 2, 5.

Differential Diagnosis Considerations

While tirzepatide is the likely culprit, exclude other causes of left lower quadrant pain with diarrhea:

Rule out infectious causes: Obtain stool studies for bacterial pathogens (including C. difficile), though it is generally safe to start symptomatic treatment with loperamide while awaiting results 7, 8. However, avoid high-dose loperamide if C. difficile is suspected due to theoretical risk of toxic megacolon 7.

Consider functional gastric outlet obstruction: Even low-dose tirzepatide can cause severe symptoms resembling gastric outlet obstruction without anatomical abnormality 9. This represents delayed gastric emptying, a known pharmacologic effect of GLP-1 receptor agonists 10, 11.

Evaluate for diverticulitis or other structural pathology: If symptoms persist after tirzepatide discontinuation or if there are fever, leukocytosis, or peritoneal signs, obtain CT imaging to exclude diverticulitis, colitis, or other acute abdominal pathology 7.

Symptomatic Management

Rehydration

• Oral rehydration solution (ORS) is first-line for mild to moderate dehydration 8.
• Intravenous isotonic fluids (lactated Ringer's or normal saline) are indicated for severe dehydration, shock, altered mental status, or failure of oral rehydration 8.
• Continue rehydration until pulse, perfusion, and mental status normalize 8.

Antidiarrheal Therapy

• Loperamide may be given to immunocompetent adults with acute watery diarrhea, starting with 4 mg followed by 2 mg every 4 hours (maximum 16 mg/day) 8, 12.
• Avoid loperamide in suspected inflammatory diarrhea or if fever is present due to risk of toxic megacolon 8.
• Reassess regularly to exclude development of toxic colonic dilatation 7.

Dietary Modifications

• Stop all lactose-containing products, alcohol, and high-osmolar supplements 12.
• Drink 8-10 large glasses of clear liquids daily (e.g., electrolyte solutions, broth) 12.
• Eat frequent small meals (bananas, rice, applesauce, toast, plain pasta) 12.
• Gradually reintroduce solid foods as symptoms resolve 12.

Long-Term Management and Prevention

Do not restart tirzepatide if symptoms were severe, as this represents a significant adverse drug reaction 1. If glycemic control or weight management remains a clinical priority after complete symptom resolution:

• Consider alternative GLP-1 receptor agonists with potentially better tolerability profiles, though cross-reactivity of gastrointestinal side effects is common 2.
• If restarting any GLP-1 receptor agonist, begin at the lowest possible dose with very slow titration 2, 13.
• Counsel patients on strategies to minimize gastrointestinal effects: eating smaller meals, drinking plenty of water, increasing dietary fiber, eating slowly, stopping when full, and avoiding high-fat or spicy foods 2.

Common Pitfalls to Avoid

• Do not attribute all abdominal symptoms to "expected" medication side effects: Always evaluate for serious complications like pancreatitis, gallbladder disease, or bowel obstruction 1.
• Do not continue tirzepatide through severe symptoms: The FDA label explicitly states the drug is not recommended in severe gastroparesis, and severe gastrointestinal reactions warrant discontinuation 1.
• Do not overlook electrolyte monitoring: Severe vomiting and diarrhea can cause life-threatening electrolyte disturbances requiring urgent correction 3.
• Do not assume symptoms will always resolve with time: While many patients develop tolerance to gastrointestinal effects, some experience persistent or worsening symptoms requiring permanent discontinuation 9, 6.